Chemotherapy and molecular targeted therapy for small intestine cancer

VernacularTitle:小肠癌化疗及分子靶向治疗
Author: Jingjing WU ; Kangsheng GU
Publication Type:Journal Article
Keywords: Intestinal neoplasms; Drug therapy; Molecular targeted therapy
From: Journal of International Oncology 2012;39(9):703-706
CountryChina
Language:Chinese
Abstract: Neoplasms of the small intestine have no specific features at early stage,and the prognosis is poor.The 5-year survival rate of all the patients is about 30％ and the middle survival time is 19 months.The retrospective analysis shows that adjuvant chemotherapy after surgical resection might improve the disease free survival while the overall survival is not improved obviously.The patients who are at advanced stage or have regional lymph node metastasis may obtain benefits from adjuvant chemotherapy.Palliative chemotherapy may improve progress free survival and overall survival of patients who are at advanced stage.The therapeutic effect of patients at advanced stage using FOLFOX regimen ( 5-fluorouracil,calcium folinate and oxaliplatin ) is better compared with other regimens.The molecular targeted therapy of small intestine cancer is still in the study process and advanced studies are also needed for chemotherapy.